Company / R&D per Share
Cullinan Therapeutics, Inc. R&D per Share History
FY2020-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$2.44
FY2024
5-year range
$1.45 / $3.57
FY2020-FY2024
Trend
-31.5%
vs FY2023
Sector context
#87 of 208
Health Care
What the data says
At $2.44, Cullinan Therapeutics, Inc.'s r&d per share ranks #87 of 208 in the Health Care sector. Improved from $2.01 to $2.44 over the past 2 years.
Based on SEC 10-K filings.
2.44 in FY2024 with a 3-year CAGR of +19.0%.
Improved from $2.01 to $2.44 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- +19.0%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#87 of 208 in Health CareTop 42% of 208This company $2.44 Sector average $28.83
▼
-91.5% below sector average
Key checks
Key Insights
- In FY2024, r&d per share decreased 31.5% year-over-year.
- Ranks #87 out of 208 companies in the Health Care sector.
- Peak r&d per share was recorded in FY2023.
- Lowest r&d per share in the period was in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 7.33 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $2.44 | -31.5% |
| FY2023 | $3.57 | +77.6% |
| FY2022 | $2.01 | +38.6% |
| FY2021 | $1.45 | -33.3% |
| FY2020 | $2.17 | - |
As of FY2024 · SEC 10-K · Updated Jul 2, 2026